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ORIGINAL
The ADVIA2120i parameter Revised %MICRO is a surrogate
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Abstract : Objectives : Hematopoietic stem cell transplantation (HSCT)-associated thrombotic microangiopathy 
(TA-TMA) is an important early post-treatment condition. This study evaluated the Revised %MICRO, a parame-
ter obtained from the ADVIA 2120i automated blood cell counter, as a surrogate marker of the schistocyte ratio. 
We hypothesized that individual differences between the %MICRO value and schistocyte ratio would remain 
constant. Design and Methods: EDTA-2K-treated peripheral blood samples were collected from 19 patients who 
underwent allogeneic HSCT from April 2014 to September 2018. First, the baseline difference, X, was calculat-
ed using a sample from the first day after HSCT as X = %MICRO (first day) – schistocyte ratio (first day). Next, 
the Revised %MICRO for each subsequent day was calculated as Revised %MICRO = %MICRO – X. We evaluated 
correlations of the schistocyte ratio with the calculated %MICRO and Revised %MICRO and the RBC fragment, 
RBC distribution width, %MICRO and Revised %MICRO data obtained from the ADVIA 2120i. Results : The mean 
schistocyte percentage and Revised %MICRO were both 0.4% ± 0.6. RBC fragments correlated weakly with the 
%MICRO and schistocyte ratio, respectively (r = 0.162 and r = 0.771, respectively), whereas the Revised %MICRO 
correlated strongly with the schistocyte ratio (r = 0.893). Conclusion : The Revised %MICRO appears to be a good 
surrogate of the schistocyte ratio in a clinical setting. J. Med. Invest. 67 : 250-254, August, 2020
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1. INTRODUCTION
 
Hematopoietic stem cell transplantation (HSCT) is a curative 
option for hematologic malignancies. In such cases, the post-pro-
cedural administration of calcineurin inhibitors such as cyclo-
sporine or tacrolimus is required to suppress graft-versus-host 
disease (GVHD). However, these drugs can lead to major com-
plications such as HSCT-associated thrombotic microangiopathy 
(TA-TMA), which was first described by Powles et al. (1). in 1980 
as endothelial cell damage induced by calcineurin inhibitors. 
Given the dismal clinical course of severe TA-TMA, an early 
diagnosis is highly desirable (2-4).
TA-TMA is characterized by the appearance of schistocytes, a 
consequence of red blood cell (RBC) passage through damaged 
blood vessels. Accordingly, the schistocyte ratio correlates with 
the severity of TA-TMA, and Zeigler et al. even developed a TA-
TMA severity classification based on this parameter (5-6). The 
guidelines of the International Council for Standardization in 
Haematology (ICSH) define a schistocyte ratio ≥ 1% as being 
a strong morphological indicator for the diagnosis of TMA (7). 
In the Japanese Society of Laboratory Hematology (JSLH), a 
schistocyte ratio ≥ 0.6% is used as an indicator for TMA as it 
allows for earlier diagnosis (8).
The enumeration of schistocytes, however, requires time, 
effort, and technical skill. Accordingly, an automated clinical 
measurement of the schistocyte ratio would greatly facilitate 
post-transplant management (9-11).
Previously, Lesesve et al. reported that when using the 
ADVIA120 automated device (Siemens Healthcare Diagnostics), 
the parameter RBC fragments, which denotes the proportion of 
RBCs with a mean corpuscular volume (MCV) < 30 fL, is a use-
ful surrogate for the post-HSCT schistocyte ratio (12-14). In this 
study, we aimed to evaluate the Revised %MICRO, a parameter 
obtained from the ADVIA 2120i blood cell counter, as a surro-
gate marker of schistocytes (Fig. 1). 
We hypothesized that individual differences between the 
%MICRO value and schistocyte ratio would remain constant. 
According to this hypothesis, we developed a new parameter, Re-
vised %MICRO, which we defined as the %MICRO value minus 
the baseline difference [%MICRO (first day) – schistocyte ratio 
(first day)]. This Revised %MICRO appears to correlate more 
strongly with the schistocyte ratio. 
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2. METHODS
2.1 Patients and samples
Peripheral blood samples were collected from 19 patients who 
underwent allogeneic HSCT from April 2014 to September 2018 
and were treated with EDTA-2K to prevent coagulation. The 
hemoglobin criterion was set at a mean corpuscular hemoglobin 
concentration (MCH) > 29.0 pg/L. This criterion yielded 7 cases 
with a schistocyte ratio > 0.6% and 12 with a schistocyte ratio 
< 0.6% (Table 1). This study protocol and consent procedure were 
approved by the Ethics Committee of Tokushima University 
Hospital (No.3319), and performed in compliance with the Hel-
sinki Declaration. 
2.2 Cell counts using ADVIA2120i
The automated cell-counting analyzer, ADVIA2120i (Siemens 
Healthcare Diagnostics), was used in this study. This device 
performs an integrated analysis of RBCs and platelets to yield a 
value for the %RBC fragments. Specifically, platelet scatter sig-
nals acquired at low (2–3º) and high angles (5–15º) are converted 
into volume and refractive index values. The platelet scatter-
gram displays cells with volumes ≤ 30 fL and refractive indices 
of 1.35–1.40. Here, we studied the correlations of the schistocyte 
ratio with the %RBC fragments and RBC distribution with 
(RDW) (Fig. 2A and 2B).
To determine the %MICRO value, the ADVIA2120i uses 
two-angle laser flow cytometry with exposing sodium dodecyl 
sulfate (SDS) to obtain isovolumetric sphering measurements 
of RBC. The scattered light from a 670-nm laser beam is used 
to measure the RBC volume and determine the MCV and 
hemoglobin level. The RBC matrix is then displayed as a plot 
of the hemoglobin level (horizontal axis) vs. the MCV (vertical 
axis). %MICRO is defined as the ratio corresponding to a MCV 
of 30–60 fL.
2.3 Microscopic enumeration of schistocytes 
Schistocytes from 4,000 May–Giemsa-stained RBCs were 
counted under a microscope (magnification, 1000×). We applied 
the following morphological criterion proposed by Dacie and 
Table 1.　Revised %MICRO and schistocyte ratios from patients 
with and without BMT related TMA
TMA Schistocyte ratios (%)
Revised 
%Micro (%)
Myelofibrosis yes 0.3 ± 0.2 0.5 ± 0.5
AML with inv (16) yes 1.7 ± 1.0 1.8 ± 1.0
AML t (11 ; 17) (q23, q25) yes 0.3 ± 0.2 0.7 ± 0.4
AML without maturation yes 0.4 ± 0.1 0.4 ± 0.2
AML t (9 ; 11) (q22 ; q23) yes 0.8 ± 0.5 0.8 ± 0.6
B-ALL no 0.1 ± 0.1 0.1 ± 0.1
AML t (11 ; 19) (q23 ; p13.1) no 0.0 ± 0.1 0.0 ± 0.0
AML with MRC no 0.3 ± 0.1 0.3 ± 0.2
AML with MRC no 0.0 ± 0.0 0.0 ± 0.0
B-ALL no 0.2 ± 0.2 0.1 ± 0.1
MDS yes 0.3 ± 0.2 0.3 ± 0.3
MDS no 0.3 ± 0.2 0.3 ± 0.2
MDS no 0.0 ± 0.0 0.0 ± 0.0
MDS no 0.0 ± 0.0 0.0 ± 0.0
MDS no 0.2 ± 0.2 0.3 ± 0.2
MDS no 0.2 ± 0.2 0.3 ± 0.3
ATLL yes 1.0 ± 0.7 0.7 ± 0.4
Hepatosplenic T cell lymphoma no 0.0 ± 0.0 0.0 ± 0.0
Granulocyticsarcoma no 0.0 ± 0.1 0.0 ± 0.0
Fig 2.　Correlations of the schistocyte ratio with red blood cell (RBC) 
parameters in 299 samples. A. Correlation with the %RBC fragment 
value. B. Correlation with the RBC distribution width (RDW). Eval-
uation was performed  299 samples obtained from 19 patients after 
HSCT.
Fig 1.　Red blood cell (RBC) matrix obtained using the ADVIA 2120i 
blood cell counter. The %MICRO displays the RBC ratio up to a mean 
corpuscular volume of 30–60 fL for total RBCs.
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Lewis to well-stained entities : 1) small and irregular, 2) helmet, 
3) sharp, and 4) small spherocyte-shaped (15). One technician 
performed all enumerations to rule out inter-operator variability. 
The schistocyte ratio was calculated as the ratio of the schisto-
cyte count to the total  RBC count.
2.4 Definition of Revised %MICRO
We hypothesized that the difference between the %MICRO 
and schistocyte ratio would remain constant in each patient. 
First, we calculated the baseline difference, X, using the sample 
of first day after HSCT as X = %MICRO (first day) – schistocytes 
ratio (first day). Next, we calculated the Revised %MICRO for 
each subsequent day as Revised %MICRO = %MICRO – X. We 
then analyzed the correlations of the schistocyte ratio with the 
%MICRO and Revised %MICRO values (Fig. 3A and 3B).
2.5 Cut-off value of the Revised %MICRO
The Japanese Society of Laboratory Hematology defined 
a schistocyte ratio > 0.6% as the cut-off value for TA-TMA. 
Therefore, we used a receiver operating characteristic curve to 
determine the Revised %MICRO cut-off value equivalent to a 
schistocyte ratio of 0.6% (8).
2.6 Statistical analysis
All statistical analyses were performed using EZR software, 
version 1.27 (Saitama Medical Center, Jichi Medical University, 
Saitama, Japan) (16). Statistical comparisons were performed 
using the parametric paired ROC curve for continuous parama-
ters depending upon normality between the TMA and non-TMA 
groups.
3. RESULTS
Our microscopic analysis of various samples revealed that 
most schistocytes are larger than 30 fL. Therefore, we focused 
on the %MICRO parameter, which denotes RBCs with a MCV of 
30–60 fL as a surrogate marker of the schistocyte ratio. The AD-
VIA2120i uses the Baso and Perox channels to perform the total 
nucleated cell count and leukocyte cell differential, respectively. 
RBCs are measured using the RBC/PLT channel, which deter-
mines all RBC counts  following exposure to sodium dodecyl 
sulfate (SDS) to yield isovolumetric sphering measurements, 
MCV, and MCH. Accordingly, we generated an RBC-scattered 
matrix for each sample using the MCV and MCH and designated 
the fraction with an MCV of 30–60 fL as the %MICRO output 
(Fig. 1).
Correlations of the schistocyte ratio with %RBC fragments 
(y = 0.06x + 0.237, r = 0.162), %MICRO (y = 0.79x + 0.696, 
r = 0.771), and Revised %MICRO (y = 0.89x + 0.064, r = 0.893) 
are shown in Fig. 2, 3A and 3B respectively. The Revised 
%MICRO was able to detect a fraction of samples with a low 
schistocyte ratio ( < 0.6%) that would have been difficult to de-
tect microscopically.
3.1 Cut-off value for Revised %MICRO
The ROC curve analysis revealed that the cut-off value of 
“Revised %MICRO” equivalent to 0.6% of schistocytes ratio was 
0.6% (same value by chance) with the sensitivity 0.852, and the 
specificity 0.821 (Fig. 4).
3.2 Example of Revised %MICRO monitoring in a case of TMA 
after HSCT
We present acute myeloid leukemia with the (inv16)
(p13.1 ; q22) CBFB-MYH11 translocation as one of the represen-
tative cases that developed TMA after HSCT.
We monitored the Revised %MICRO and schistocyte ratio 
in the case of TA-TMA. The schistocyte ratio began to increase 
Fig 3.　Correlations of the schistocyte ratio with ADVIA 2120i pa-
rameters in 299 samples. A. Correlation with the %MICRO, which de-
notes red blood cells (RBC) with a mean corpuscular volume of 30–60 
fL. B. Correlation with the Revised %MICRO.
Fig 4.　Determination of the cut-off value for the schistocyte ratio 
using receiver operating characteristic (ROC) curves of the Revised 
%MICRO.
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on day 60 after HSCT and reached 3.6% on day 81. The patient 
was switched from tacrolimus to cyclosporine, and prednisolone 
was initiated with recombinant thrombomodulin. Subsequent-
ly, the patient’s schistocyte ratio decreased to 1.5% but began 
to increase again on day 192. The association of the Revised 
%MICRO value with the schistocyte ratio remained consistent 
throughout the patient’s clinical course (Fig. 5A and 5B). 
 
4. DISCUSSION
As noted above, TA-TMA is characterized by the induction 
of schistocytes in the peripheral blood in response to passage 
through damaged vascular endothelium. Although the quanti-
tative monitoring of the schistocyte ratio is provides a critical 
assessment of TA-TMA, manual microscopic counting is chal-
lenging and subject to inter-operator variance. We previously re-
ported that the %MICRO, a parameter automatically generated 
by the ADVIA2120i device, exhibits a good correlation with the 
microscopic schistocyte ratio and may thus be a useful surrogate 
marker (17). However, poikilocytes, a characteristic of iron-defi-
cient anemia, can yield falsely high %MICRO values. We found 
that because of these poikilocytes, the %MICRO values were not 
consistent with the schistocyte ratios in the context of hypochro-
mic anemia (low MCH). Therefore, we focused on samples with 
MCH vales > 29.0 pg/L. Furthermore, schistocytes also appear 
in the context of various diseases such as sporadic hemolytic-ure-
mic syndrome (HUS) / thrombotic thrombocytopenic purpura 
(TTP), burn injury, and scleroderma-related renal crisis. There-
fore, the pathogenesis of TMA may interact with discrepancies 
between the physiologic properties and morphology and thus af-
fect the difference between the %MICRO value and the schisto-
cyte ratio. To clarify the significance of %MICRO, we focused 
this study on the post-transplant context and aimed to identify 
the best association between the %MICRO value and schisto-
cyte ratio. We observed a weak correlation between %RBC 
fragments and the schistocyte ratio, which can be explained 
by the exclusion of patients with marked schistocyte diseases 
such as TTP/HUS. Accordingly, the %RBC fragments would 
not be associated microscopically with the schistocyte zone. In 
contrast, we observed a moderate correlation of %MICRO with 
the schistocyte ratio. However, the %MICRO value was always 
higher than the schistocyte ratio, which might be attributed 
to the nature of the parameters. While a microscopic analysis 
would only count small RBCs (MCV ~30–60 fL) with a high 
MCH as schistocytes, %MICRO includes all RBCs with a MCV 
of 30–60 fL, regardless of hemoglobinemia. To exclude the low 
hemoglobinemia fraction from small RBC, we hypothesized 
that 1) the magnitude of the low-hemoglobin fraction would vary 
among HSCT patients but 2) the variance would remain small 
within each patient. Therefore, to reduce noise and address the 
observation that the %MICRO value was always higher than 
the schistocyte ratio, we developed a new parameter, Revised 
%MICRO, which was shown to exhibit a much stronger correla-
tion with the schistocyte ratio. By chance, the cut-off Revised 
%MICRO value corresponding to a 0.6% schistocyte ratio was 
also 0.6%, based on the valance of sensitivity and specificity. 
However, given the trend towards a moderately higher Revised 
%MICRO value relative to the schistocyte ratio when the former 
value exceeds 0.6%, microscopic counts should also be performed 
during post-HSCT monitoring. 
We further investigated the association of Revised %MICRO 
with the RDW, which was previously reported to associate with 
the schistocyte ratio (18).  However, we found that the Revised 
%MICRO” correlated more precisely with the schistocyte ratio, 
as the sensitivities for the interactions of the schistocyte ratio 
with %RBC fragments and RDW were too low to enable clinical 
monitoring in cases with schistocyte counts < 1.0%. In other 
words, among the ADVIA2120i-derived parameters, Revised 
%MICRO exhibited the best relationship with the schistocyte 
ratio even at low values of the latter. Possibly, microscopic de-
termination of the schistocyte ratio in cases with an increasing 
Revised %MICRO may be an effective means of avoiding overt 
TA-TMA. 
Fig 5.　Representative patient data. A. A case of acute myeloid leukemia in a patient harboring the inv (16) (p13.1q22) mutation 
(CBFB-MYH11 translocation). A post-hematopoietic stem cell transplantation (HSCT) analysis reveals that the Revised %MICRO 
reflected the schistocyte ratio rather than the red blood cell (RBC) distribution width (RDW) trend. B. RBC morphology in peripheral 
blood at the time of the peak of schistocyte ratio, 81 days after HSCT.
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In conclusion, Revised %MICRO exhibited the strongest cor-
relation with the schistocyte ratio among all tested ADVIA2120i 
parameters. Moreover, Revised %MICRO enabled accurate 
monitoring even in cases with low schistocyte ratios ( < 1.0%). To 
put the schistocytes ratio chosen under the microscope into effect 
seems watching a fluctuation of the schistocytes ratio Revised 
%MICRO, and when admitting the increased tendency, import-
ant to stop TMA after hematopoietic stem cell transplantation .
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